https://orcid.org/0000-0003-4232-8146
References
- Kong M, Zhou C, Zhu K, et al. 12-month teriparatide treatment reduces new vertebral compression fractures incidence and back pain and improves quality of life after percutaneous kyphoplasty in osteoporotic women. Clin Interv Aging. 2019;14:1693–1703. doi:10.2147/CIA.S22466331631990
- McCarthy J, Davis A. Diagnosis and management of vertebral compression fractures. Am Fam Physician. 2016;94(1):44–50.27386723
- Tsoumakidou G, Too CW, Koch G, et al. CIRSE guidelines on percutaneous vertebral augmentation. Cardiovasc Intervent Radiol. 2017;40(3):331–342. doi:10.1007/s00270-017-1574-828105496
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi:10.1056/NEJM20010510344190411346808
- Tu PH, Liu ZH, Lee ST, Chen JF. Treatment of repeated and multiple new-onset osteoporotic vertebral compression fractures with teriparatide. J Clin Neurosci. 2012;19(4):532–535. doi:10.1016/j.jocn.2011.04.04822341147
- Zhao Y, Xue R, Shi N, et al. Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications. Osteoporosis Int. 2016;27(11):3309–3317. doi:10.1007/s00198-016-3651-2
- Min HK, Ahn JH, Ha KY, et al. Effects of anti-osteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures: a retrospective analysis of prospectively designed study. Osteoporosis Int. 2019;30(11):2249–2256. doi:10.1007/s00198-019-05125-0
- Ebeling PR, Akesson K, Bauer DC, et al. The efficacy and safety of vertebral augmentation: a second asbmr task force report. J Bone Mineral Res. 2019;34(1):3–21. doi:10.1002/jbmr.v34.1